イメージ
大分大学医学部附属病院薬剤部
 
業　績（原著論文）

原著論文（2019年 2018年 2017年 2016年 2015年 2014年 2013年 2012年 2011年 2010年

2019年
  1. Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Tanaka R, Yasuda N, Kai S, Kitano T, Suzuki Y, Sato Y, Koga H, Goto K, Ohchi Y, Itoh H, J Pharm Biomed Anal, 165, 56-64 (2019)
  2. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients. Suzuki Y, Muraya N, Fujioka T, Sato F, Tanaka R, Matsumoto K, Sato Y, Ohno K, Mimata H, Kishino S, Itoh H. Pharmacol Rep, 71, 276-281 (2019)
  3. Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease. Suzuki Y, Ono H, Tanaka R, Sato F, Sato Y, Ohno K, Mimata H, Itoh H. Pharm Res, 36(4),59 (2019)
  4. High-sensitivity simultaneous quantification of tacrolimus and 13-O-demethyl tacrolimus in human whole blood using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Ono H, Suzuki Y, Kaneko T, Tanaka R, Sato F, Sato Y, Mimata H, Itoh H. Biomed Chromatogr, 33(9), e4584 (2019)
  5. Comparison of performance characteristics between high-performance liquid chromatography and latex agglutination turbidimetric immunoassay for therapeutic drug monitoring of zonisamide. Eto D, Tanaka R, Suzuki Y, Sato Y, Itoh H. J Clin Lab Anal. 33(7), e22940 (2019)
  6. Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report. Nakahara R, Sumimoto T, Ogata M, Sato Y, Itoh H. Clin Case Rep. 7(7), 1419-1421 (2019)
2018年
  1. A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection. Sumimoto T, Nakahara R, Sato Y, Itoh H, J Clin Lab Anal. 32, 1-3 (2018)
  2. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy. Sato Y, Hiramatsu K, Suzuki Y,Tanaka R, Kaneko T, Nonoshita K, Ogata M, Kadota JI, Itoh H. Chemotherapy. 63(1),29-34(2018)
  3. Comparison of whole blood tacrolimus concentrations measured by different immunoassay systems Kaneko T, Fujioka T, Suzuki Y, Nagano T, Sato Y Itoh H, J Clin Lab Anal. 32, e22587(2018)
  4. Filgrastim biosimilar for neutropenia in gynecological cancer patients receiving chemotherapy: a prospective, single-center, non-randomized, open trial. Sato Y, Sumimoto T, Tsushita H, Nakahara R, Matsumoto H, Itoh H, Pharmazie. 8, 486-488(2018)
2017年
  1. Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Suzuki Y, Witt L, Mier W, Mikus G, Markert C, Haefeli WE, Burhenne J. J Pharm Biomed Anal, 142,84-90 (2017)
  2. Pharmacokinetic/pharmacodynamic analysis for doripenem regimens in intensive care unit patient. Tanaka R, Sato Y, Goto K, Yasuda N, Ohchi Y, Suzuki Y, Ito K, Kaneko T, Nonoshita K, Itoh H. Biol Pharm Bull,40(8),1226-1231 (2017)
  3. Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Suzuki Y, Tanaka R, Oyama N, Nonoshita K, Hashinaga K, Umeki K, Sato Y, Hiramatsu K, Kadota JI, Itoh H. Clin Biochem, 50(18),1228-1236 (2017)
2016年
  1. Performance characteristics between TDxRFLx and TBA-25FR for the therapeutic drug monitoring of methotrexate. Kaneko T, Fujioka T, Suzuki Y, Sato Y, Itoh H, J Pharm Health Care Sci. 8, 2-7 (2016)
  2. High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in human plasma from patients with chronic myelogenous leukemia, and comparison with liquid chromatography-tndem mass spectrometry. Nakahara R, Sato Y, Itoh H, J Clin Lab Anal. 30(6),1028-1030 (2016).
  3. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1027,207-213 (2016)
  4. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy. Goto K, Sato Y, Yasuda N, Hidaka S,Suzuki Y, Tanaka R, Kaneko T, Nonoshita K, Itoh H, J Basic Clin Physiol Pharmacol. 27(6), 625-631(2016)
  5. Clinical implications of plasma N-acetyl-seryl-aspartyl-lysyl-proline level in stable kidney transplant recipients Suzuki Y, Katagiri F, Sato F, Fujioka K, Sato Y, Fujioka T, Sato Y, Mimata H, Itoh H. Clin Lab, 62, 1323-1328 (2016)
  6. A retrospective analysis of risk factors for linezolid-associated hyponatremia in Japanese patients.Tanaka R,Suzuki Y,Takumi Y,Iwao M,Sato Y,Hashinaga K,Hiramatsu K,Kadota JI, Itoh H. Biol.Pharm.Bull, 39(12),1968-1973(2016)
2015年
  1. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Suzuki Y., Tokimatsu I., Morinaga Y., Sato Y., Takano K., Kohno K., Ogata M., Hiramatsu K., Itoh H., Kadota JI., Clin. Chim. Acta., 440, 183-187 (2015)
  2. Significance of high trough concentration of teicoplanin in the treatment of methicillin-resistant Staphylococcus aureus infection. Sato Y., Tokimatsu I.,Suzuki Y.,Itoh H.,Hiramatsu K., Kadota JI., Chemotherapy.,60, 274-278 (2015)
  3. CYP3A5 polymorphism affects the increase in CYP 3A activity after living kidney trasplantation in patients with end stage renal disease, Suzuki Y., Fujioka T., Sato F., Matsumoto K, Muraya N., Tanaka R., Sato Y., Ohno K., Mimata H., Kishino S., Itoh H. Br.J.Clin.Pharm. 80(6),1421-1428 (2015)
  4. Effect of goshajinkigan, a Japanese herbal medicine, on the plasma neuropeptides in humans. Sato Y, Tatsuta R, Suzuki Y, Itoh H, Clinical Research and Trial. 1(2), 34-37 (2015)
  5. Association of metabolic complications with plasma mid-regional pro-adrenomedullin level in stable kidney transplant recipients. Suzuki Y, Katagiri F, Sato F, Fujioka T, Tanaka R, Sato Y, Mimata H, Itoh H., Clin. Chim. Acta., 453, 160-163 (2015)
2014年
  1. Association of Plasma Concentration of 4β-Hydroxycholesterol with CYP3A5 Polymorphism and Plasma Concentration of Indoxyl Sulfate in Stable Kidney Transplant Recipients. Suzuki Y., Itoh H., Fujioka T., Sato F., Kawasaki K., Sato Y., Sato Y., Ohno K., Mimata H., Kishino S., Drug Metab. Dispos., 42, 105-110 (2014)
  2. Significant Decrease in Plasma N-Acetyl-seryl-aspartyl-lysyl-proline Level in Patients with End Stage Renal Disease after Kidney Transplantation. Suzuki Y., Katagiri F., Sato F., Fujioka K., Sato Y., Fujioka T., Sato Y., Mimata H., Itoh H., Biol. Pharm. Bull., 37(6), 1075-1079 (2014).
  3. Therapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study. Kayamaya Y, Terao K, Kamei K, Hatano K, Kohno K, Makino M, Mizokami Y, Kodama K, Itoh H, Pharmacopsychiatry, 47, 111-114 (2014)
  4. Darbepoetin Alfa Increases Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Kidney Transplant Recipient: A Case Report. Suzuki Y., Katagiri F., Sato F., Sato Y., Mimata H., Itoh H., J.Transplant.Technol.Res., 4, 1-3 (2014)
2013年
  1. Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma. Sato Y, Itoh H, Suzuki Y, Tatsuta R, Takeyama M. J Clin Pharm Ther, 38, 19-23 (2013)
  2. Interaction between Pirenzepine and Ninjinto, a Traditional Japanese Herbal Medicine, on the Plasma Gut-Regulated Peptide Levels in Humans, Sato Y, Itoh H, Suzuki Y, Tatsuta R, Takeyama M, Int J Pept, 2013, 5 (2013)
  3. Development and clinical application of an enzyme immunoassay for the determination of midregional proadrenomedullin. Suzuki Y., Itoh H., Katagiri F., Sato F., Sato Y., Kawasaki K., Sato Y., Mimata H., Takeyama M., J. Pept. Sci., 19, 59-63 (2013)
  4. Significant decrease in plasma midregional proadrenomedullin level in patients with end-stage renal disease after living kidney transplantation. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Sato Y., Mimata H., Takeyama M., Peptides, 43, 102-104 (2013)
  5. Significant Increase in Salivary Substance P Level after a Single Oral Dose of Cevimeline in Humans. Suzuki Y., Itoh H., Amada K., Yamamura R., Sato Y., Takeyama M., Int. J. Pept., 2013, 284765 (2013
  6. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Suzuki Y., Tokimatsu I., Sato Y., Kawasaki K., Sato Y., Goto T., Hashinaga K., Itoh H., Hiramatsu K., Kadota JI., Clin. Chim. Acta., 424, 119-122 (2013)
  7. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. Suzuki Y., Itoh H., Sato F., Kawasaki K., Sato Y., Fujioka T., Sato Y., Ohno K., Mimata H., Kishino S., J. Lipid Res., 54, 2568-2572 (2013)
  8. Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Sato Y., Mimata H., Takeyama M., Peptides, 48, 45-48 (2013)
  9. Affective temperaments and psychotropic adherence. Kamei K., Terao T., Katayama Y., Hoaki N., J Affect Disord, 150（3）1142-1147(2013)
2012年
  1. Mirtazapine suppresses the increases in plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure. Suzuki Y., Itoh H., Abe T., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 1-5 (2012)
  2. Comparison of the effects of pantethine and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure. Itoh H., Suzuki Y., Yamamura R., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 41-44 (2012)
  3. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy. Itoh H., Suzuki Y., Fujisaki K., Sato Y., Takeyama M., Biol. Pharm. Bull., 35, 971-974 (2012)
  4. Significant increase in salivary substance P level after a single oral dose of Japanese herbal medicine Dai-kenchu-to in humans. Suzuki Y., Itoh H., Yamamura R., Tatsuta R., Sato Y., Takeyama M., Biomedicine & Aging Pathology, 2, 81-84 (2012)
  5. Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N-acetyl-seryl-aspartyl-lysyl-proline. Suzuki Y., Itoh H., Katagiri F., Sato F., Kawasaki K., Sato Y., Mimata H., Takeyama M., J. Pept. Sci., 18, 276-281 (2012)
  6. Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia. Suzuki Y., Kawasaki K., Sato Y., Tokimatsu I., Itoh H., Hiramatsu K., Takeyama M., Kadota JI., Chemotherapy, 58, 308-312 (2012)
2011年
  1. Sodium alginate as an ideal submucosal injection material for endoscopic submucosal resection: preliminary experimental and clinical study. Akagi T, Yasuda K, Tajima M, Suzuki K, Inomata M, Shiraishi N, Sato Y, Kitano S. Gastrointest Endosc. 74(5), 1026-32 (2011)
  2. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy. Suzuki Y., Itoh H., Abe T., Nishimura F., Sato Y., Takeyama M., J. Pharm. Pharmacol., 63, 976-981 (2011)
  3. Comparison of the effects of pantethine and fursultiamine on plasma gastrointestinal peptide levels in healthy volunteers. Suzuki Y., Itoh H., Abe T., Nishimura F., Sato Y., Takeyama M., Biol. Pharm. Bull., 34, 1640-1643 (2011)
2010年
    　　　　　　
  1. Daikenchuto raises plasma levels of motilin in cancer patients with morphine-induced constipation. Sato Y, Itoh H, Takeyama M. J. Trad. Med., 26(3), 122-130 (2010)